Abstract

In this talk I will describe the application of the latest advances in high content imaging to profile drug mechanism of action across complex 2D and 3D in vitro models of cancer, neurodegenerative disease and liver disease. I will present examples of how combining the latest advances in multiparametric high content imaging with other omics technologies and emerging Artificial Intelligence/Machine Learning solutions elucidates drug mechanism-of-action tailored toward addressing complex disease phenotypes. I will present a case study describing the discovery of a novel Src/Yes1 inhibitor with a unique binding mode-of-action to target cancers of unmet need.